Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The collagen matrix is not a single molecule or solitary therapeutic target but a complex three-dimensional extracellular network formed primarily from collagen protein fibers, especially type I collagen[1][2][3][6]. This matrix is the principal component of the extracellular matrix (ECM), giving structural integrity and mechanical strength to connective tissues such as bone, skin, tendons, and cartilage[1][2][5][6][8]. Collagen fibers are composed of triple-helical molecules (tropocollagen) that aggregate into fibrils and further assemble into larger fibers and networks, where their alignment and crosslinking determine the mechanical properties and organization of tissues[1][3][5][6][8]. Beyond providing structural support, the collagen matrix serves as a scaffold for cell adhesion, migration, and regulation of cellular function, influencing processes such as stem cell differentiation, wound healing, and tissue development[2][3][4]. Abnormalities or excessive deposition in the collagen matrix are associated with pathologies such as fibrosis, certain cancers, and inherited connective tissue disorders[4][9]. While enzymes (such as collagenases) may therapeutically target the collagen matrix in some disease contexts, the matrix itself is not a conventional drug target like a receptor or enzyme, but rather a structural element or pathological substrate and thus is not classified as a typical therapeutic target[1][5][9]. Key notes: - The collagen matrix is a multi-molecular scaffold and not a single molecule; it cannot be equated to a traditional molecular drug target such as a receptor, enzyme, or transporter[2][3][4]. - Common references to the “collagen matrix” typically refer to the network or environment of collagen molecules in tissues, not a discrete gene or protein product[1]. - Therapeutic strategies often aim to modify the matrix (e.g., by using collagenases or matrix metalloproteases), not directly inhibit or activate it as a drug target[9]. If you require information on a specific collagen type as a molecular target (such as "Collagen type I alpha 1 chain"), please specify, as this would allow for a molecular-level target summary.
Enzymatic degradation of collagen matrix (e.g., by collagenase)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen matrix.